

Date of submission: 8<sup>th</sup> February 2023

To, The Secretary Listing Department <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 539551	To, The Secretary Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Code- NH
---	---

Dear Sir/Madam,

**Sub: Press Release for the Quarter and nine months ended 31<sup>st</sup> December 2022 and Call invite**

With reference to the subject, please find enclosed Press Release for the Quarter and nine months ended 31<sup>st</sup> December 2022 and call invite to discuss the Company's performance on Friday, 10<sup>th</sup> February 2023 at 2:30 P.M. (IST).

Kindly take the above information on record.

Thanking you.

Yours faithfully  
For **Narayana Hrudayalaya Limited**

Sridhar S.  
Group Company Secretary, Legal & Compliance Officer

Encl.: as above

**Q3 FY23 Consolidated operating income at Rs 11,282 mn (Y-o-Y of 17.5%) with EBITDA\* of Rs 2,660 mn (Y-o-Y of 46.3%)**  
**9M FY23 Consolidated operating income at Rs 33,032 mn (Y-o-Y of 19.7%) with EBITDA\* of Rs 7,408 mn (Y-o-Y of 47.2%)**

**Bengaluru, India, February 8<sup>th</sup>, 2023** – Narayana Hrudayalaya Limited, a leading healthcare provider in India, announced its financial results for the third quarter (Q3 FY23) ended December 31<sup>st</sup>, 2022.

#### **Financial Highlights for the Quarter (Q3 FY23)** - Prepared in accordance with Ind AS ('Indian Accounting Standards')

- Consolidated total operating income was Rs 11,282 mn for Q3 FY23 as compared to Rs 9,598 mn in the corresponding period of the previous year, reflecting an increase of 17.5% YoY and decline of 1.2% QoQ
- Consolidated EBITDA\* stood at Rs 2,660 mn, reflecting a margin of 23.6% as against Rs 1,819 mn in Q3 FY22, translating into YoY growth of 46.3% and QoQ degrowth of 3.2% respectively
- Consolidated PAT\* stood at Rs 1,539 mn, reflecting a margin of 13.6% as compared to Rs 975 mn in Q3 FY 22, translating into YoY growth of 57.7% and QoQ degrowth of 8.9% respectively

#### **Financial Highlights for the Nine Months (9M FY23)**

- Consolidated total operating income was Rs 33,032 mn for 9M FY23 as compared to Rs 27,606 mn in 9M FY 22
- Consolidated EBITDA\* of Rs 7,408 mn for 9M FY23, reflecting a margin of 22.4% as against Rs 5,032 mn in 9M FY 22
- Consolidated PAT\* stood at Rs 4,333 mn for 9M FY23, reflecting a margin of 13.1% as compared to Rs 2,732 mn in 9M FY 22

*\* This is as per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in Rs 118.6 mn increase in EBITDA and increase of Rs 0.4 mn in PAT for Q3 FY 23 and Rs 409.1 mn increase in EBITDA and increase of Rs 8.4 mn in PAT for 9M FY23 on a like-to-like basis (pre-IND AS 116)*

As on December 31<sup>st</sup>, 2022, the Total Borrowings less Cash & Bank Balance and Current Investments was Rs. 2,142 mn representing a net debt to equity ratio of 0.11. (Out of which, borrowings worth US\$ 33.3 mn is foreign currency denominated).

#### **Other Highlights during the Quarter**

- Rabindranath Tagore International Institute of Cardiac Sciences (RTIICS), Kolkata has successfully conducted Robotic Partial Nephrectomy on a patient with Single Kidney
- Mazumdar Shaw Medical Centre (MSMC), Bengaluru performed the highest number of Robotic Gynaecological Procedures for benign conditions and reached the milestone of 150 successful Complex Airway Reconstructions and touched about 1,500 patient base for complex aerodigestive anomalies & problems till date
- SRCC Children's Hospital, Mumbai achieved the highest quarterly volumes of 18 successful BMT procedures
- NH Mysore performed some cutting-edge & complex clinical procedures in the Interventional radiology and GI Sciences segments in the quarter such as
  - TIPS procedure performed in view of Budd Chiari Syndrome and Hyperthermic Intraperitoneal Chemotherapy procedure
  - Laparoscopic Heller Cardiomyotomy with Toupet Fundoplication performed for achalasia cardia

#### **Management Comment**

Commenting on the performance, **Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited**, said *"Despite several holidays and festivals which affect patient footfall, the third quarter delivered steady performance supported by the growth in business across our flagship units, newer hospitals and improvement in payor mix. However, contribution from international patient footfalls remain unaffected. Our Cayman unit managed to contribute to the overall performance despite the holiday season and we remain optimistic on strong growth prospects of overseas business.*

*We continue to strengthen our current position and grow our brand through several strategic initiatives that will drive our vision to offer integrated healthcare services to people across our core geographies."*

#### **About Narayana Hrudayalaya Limited**

Founded in 2000 by Dr. Devi Prasad Shetty and headquartered in Bengaluru, Narayana Hrudayalaya Limited is one of the leading healthcare service providers in India, operating a chain of multispecialty, tertiary and primary healthcare facilities. The Company has a network of 20 hospitals and 4 heart centres across India and Cayman Islands with over 6,100 operational beds and potential capacity of 6,370 beds.

For further details, please contact [investorrelations@narayanahealth.org](mailto:investorrelations@narayanahealth.org)

### Q3 FY23 Result Conference Call

At 2:30 PM, IST on February 10<sup>th</sup>, 2023

Following the announcement of the third quarter (Q3 FY23) ended December 31<sup>st</sup>, 2022 results, the management of Narayana Hrudayalaya Limited will host a conference call to discuss the Company's performance on February 10<sup>th</sup>, 2023 at 2:30 pm IST.

Details of the conference call are as under:

<b>Date:</b>	Friday, February 10 <sup>th</sup> , 2023										
<b>Time:</b>	2:30 pm IST										
<b>Dial-in Details:</b>											
<b>Details of Conference call</b>	<p style="text-align: center;"><a href="#">Click here to Join the Conference Call</a></p> <p>Meeting ID: 882 3528 9236</p> <p>Passcode: 864282</p> <p><b><u>Conference dial-in by your location</u></b></p> <table border="1"><tr><td>US</td><td>▪ +1 646 931 3860</td></tr><tr><td>Singapore</td><td>▪ +65 3129 4891</td></tr><tr><td>Mexico</td><td>▪ +52 558 659 6002</td></tr><tr><td>Russia</td><td>▪ +7 499 951 6379</td></tr><tr><td>Japan</td><td>▪ +81 3 4579 0432</td></tr></table>	US	▪ +1 646 931 3860	Singapore	▪ +65 3129 4891	Mexico	▪ +52 558 659 6002	Russia	▪ +7 499 951 6379	Japan	▪ +81 3 4579 0432
US	▪ +1 646 931 3860										
Singapore	▪ +65 3129 4891										
Mexico	▪ +52 558 659 6002										
Russia	▪ +7 499 951 6379										
Japan	▪ +81 3 4579 0432										
<b>Transcript</b>	The transcript will be uploaded on our website <a href="http://www.narayanahealth.org">www.narayanahealth.org</a>										